We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
West is thrilled to announce that Lisa Bakazias, VP, Operations, Manufacturing Strategy, was recently named as our 2018 HBA Luminary.
Through our Women Investing and Networking (WIN) group, West has been engaged as a corporate member of the HBA for the last four years. Each year, West selects a Luminary Award recipient based on criteria set forth by the HBA. Luminaries must have more than 20 years of professional experience, serve as a role model in their company, actively mentor and sponsor others, help women to advance their careers, exhibit dedication to the healthcare industry, and overall set a shining example of transformational leadership.
Lisa has demonstrated all of these attributes throughout her career, and especially in her time with West. She has served as a role model for many of our employees, has consistently demonstrated a commitment to embracing West’s business strategy, is a champion for change and avid supporter of WIN, and an outstanding leader. She is well-regarded, not only at West but in our industry. In addition to serving on many teams within West, she is a member of the Council of Supply Chain Management Professionals.
Lisa has been with West since 2014. Upon joining us, she immediately began making a positive impact and has since taken on positions of increasing responsibility in our supply and operations network functions. In her current role, Lisa and her team lead the global manufacturing and network optimization strategy to deliver a simplified, optimized and integrated network.
Lisa was celebrated among her peers at a special WIN Reception held at West’s corporate headquarters in Exton, PA, on Tuesday, May 1. She was formally recognized at the 2018 HBA Women of the Year event on Thursday, May 3 in New York City.
Congratulations to Lisa on this well-deserved recognition! We are thrilled to recognize her achievements and contributions as our 2018 HBA Luminary.
The challenge of assuring integrity of a sterile package is more complicated than many realize. As such, drug formulators in pharmaceutical and biotechnology companies often times underestimate the potential impact of the primary packages they select. A critical aspect to understand is container closure integrity (CCI) and leakage (i.e., failure of CCI or package integrity), is a major quality issue for sterile injectable products, as shown below.
We are proud to announce that our 2019 Corporate Responsibility Report has been published and is now live on the West website. In its fourth year, West’s 2019 Corporate Responsibility Report provides insight into West’s initiatives in Environmental Sustainability, as well as five other impact pillars – Health and Safety; Quality; Compliance and Ethics; Diversity and Talent; and Philanthropy.
The glass transition temperature (T<sub>g</sub>) is the temperature at which a material loses its viscoelastic properties. It is also indicative of the lowest temperature at which the polymer system will retain its functionality.
This week, West is delighted to be at the Parenteral Drug Association (PDA) Europe Annual Meeting in Berlin, Germany. During the show, we will provide more information on our <a href="/zh-cn/products/prefillable-systems/syringe-components/rigid-needle-shields-and-tip-caps">Rigid Needle Shield </a>(RNS). Designed to provide added safety for prefilled syringes with a staked needle, the West RNS helps assure the integrity of injectable drug products. The West RNS will be showcased along with West’s comprehensive product portfolio and technical insights.
When it comes to filing time, the last thing you need is a surprise. The pharmaceutical industry focus on issues of extractables and leachables (E&L) from packaging/delivery systems began during the mid-1990s. Since then, regulatory agency awareness of these issues has increased, while drug product formulations and other drug product contact materials have become more complex. When agency questions on extractables and leachables do arise, the process to evaluate them can seem overwhelming. As a result, many customers are asking: “Do I really need to complete all of the testing requested?”; “What does West already know about the elastomer formulation I am using?” or “Where do I start?”
English
Chinese
